Evidence map›Paper›PMID 39925684›Full record

ArticleInternational journal of nanomedicine2025

Study on the Regulated Cell Death of Hypertrophic H9c2 Cells Induced by Au:Ag Nanoparticles.

Andrés G Galindo-Padrón, Helen Yarimet Lorenzo-Anota, Mayte Rueda-Munguía, Alejandra García-Carrasco, Mabel Gaitán López, Eduardo Vázquez-Garza, Enrique Campos-González, Omar Lozano, Jorge L Cholula-Díaz

Abstract read
In one paragraph

Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Andrés G Galindo-Padrón *School of Engineering and Sciences, Tecnologico de Monterrey, Monterrey, Nuevo Leon, Mexico.ORCID 0009-0006-0692-2008
Helen Yarimet Lorenzo-Anota *Institute for Obesity Research, Tecnologico de Monterrey, Monterrey, Nuevo Leon, Mexico.ORCID 0000-0001-9560-4357
Mayte Rueda-MunguíaInstitute for Obesity Research, Tecnologico de Monterrey, Monterrey, Nuevo Leon, Mexico.
Alejandra García-CarrascoSchool of Engineering and Sciences, Tecnologico de Monterrey, Monterrey, Nuevo Leon, Mexico.ORCID 0009-0002-8658-1127
Mabel Gaitán LópezSchool of Engineering and Sciences, Tecnologico de Monterrey, Monterrey, Nuevo Leon, Mexico.ORCID 0009-0007-8522-5979
Eduardo Vázquez-GarzaInstitute for Obesity Research, Tecnologico de Monterrey, Monterrey, Nuevo Leon, Mexico.
Enrique Campos-GonzálezDepartamento de Física, Instituto Nacional de Investigaciones Nucleares, Ocoyoacac, Mexico.
Omar LozanoInstitute for Obesity Research, Tecnologico de Monterrey, Monterrey, Nuevo Leon, Mexico.ORCID 0000-0003-3156-5779
Jorge L Cholula-DíazSchool of Engineering and Sciences, Tecnologico de Monterrey, Monterrey, Nuevo Leon, Mexico.ORCID 0000-0002-4457-1572

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Aim: Over the past years, noble metal-based nanoparticles have been extensively investigated for their applications in nanomedicine. However, there are still concerns about the potential adversities that these nanoparticles may present in an organism. In particular, whether they could cause an exacerbated cytotoxic response in susceptible tissues due to damage or disease, such as the heart, liver, spleen, or kidneys. In this regard, this study aims to evaluate the cytotoxicity of mono- and bimetallic nanoparticles of gold and silver (Au:Ag NPs) on healthy and hypertrophic cardiac H9c2 cells, and on healthy and metabolically activated macrophages derived from U937 cells. The main objective of this work is to explore the susceptibility of cells due to exposure to Au:Ag NPs in conditions representing cardiometabolic diseases. Methods: Au:Ag NPs were synthesized in different molar ratios (Au:Ag, 100:0, 75:25, 50:50, 25:75, 0:100) using starch as a capping and reducing agent. Their physicochemical properties were characterized through UV-vis spectroscopy, X-ray diffraction (XRD), Fourier transform infrared (FTIR) spectroscopy, dynamic light scattering (DLS), ζ-potential measurements, and transmission electron microscopy (TEM). Moreover, the effect of the metal-based nanoparticle exposure on healthy and hypertrophic H9c2 cells was measured by analyzing the cellular vitality, the loss of mitochondrial membrane potential (∆Ψm), and the production of mitochondrial reactive oxygen species (mROS). Results: The Au:Ag NPs did not affect the cell vitality of healthy or metabolically activated macrophages. On the contrary, healthy H9c2 cells showed decreased mitochondrial metabolism when exposed to NPs with higher Ag concentrations. Furthermore, hypertrophic H9c2 cells were more susceptible to the same NPs compared to their non-hypertrophic counterparts, and presented a pronounced loss of ∆Ψm. In addition, these NPs increased the production of mROS and regulated cell death in both cardiac cells. Conclusion: In conclusion, low doses of high-Ag load in Au:Ag NPs produced cytotoxicity on H9c2 cardiac cells, with hypertrophic cells being more susceptible. These results suggest that cardiac hypertrophic conditions are more prone to a cytotoxic response in the presence of bimetallic Au:Ag NPs compared to healthy cells. In addition, this work opens the door to explore the nanotoxicity of noble metal-based NPs in biological disease conditions.

Indexed as

GoldMetal NanoparticlesMyocytes, CardiacSilverAnimalsCell DeathCell LineCell SurvivalHumansMacrophagesMembrane Potential, MitochondrialRatsReactive Oxygen SpeciesU937 CellsGoldReactive Oxygen SpeciesSilverbimetallic nanoparticlescardiovascular diseasehypertrophic cardiomyoblastsmetabolically activated macrophages

Identifiers

PMID39925684
PMCPMC11804235

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.